Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has just signed license agreements for its world-leading PromarkerD predictive test for diabetic kidney disease with USA and Mexico partners.
NEW YORK, June 22, 2018 /PRNewswire/ — PromarkerD, a simple blood test kit that uses a unique protein ‘fingerprint’ to provide early detection of the onset of diabetic kidney disease, can offer accurate testing of the more than 43 million people with diabetes in USA and Mexico — and even people with pre-diabetes.
Proteomics International Managing Director Dr Richard Lipscombe
PromarkerD is the first test able to predict the onset of diabetic kidney disease, saving lives and billions in healthcare dollars by warning of a decline in kidney function up to four years in advance.
Proteomics International Managing Director Dr Richard Lipscombe is at the American Diabetes Association 78th Scientific Sessions (June 22-26, 2018, Orlando, Florida) to discuss PromarkerD license deals.
About the USA license agreement with PrismHealthDx, Inc. (PHDx)
- USA PromarkerD launch targets the world’s biggest spending country on diabetes care
- World–leading predictive test can save and extend lives by avoiding diabetic kidney disease
- Test to be offered to patients through a partnership with precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx)
- PHDx will launch the PromarkerD test nationally
- Potential to save US healthcare system billions of dollars in treatment and dialysis costs
About the Mexico license agreement with Patia Biopharma
- Diabetes is responsible for one in seven deaths in Mexico, killing more people than cancer
- Mexico has one of the highest rates of diabetes in the world, with 13 million adults suffering from the condition
- Through Patia’s network the test will initially be introduced to private hospitals and private clinics, and then expanded into government hospitals and Carlos Slim Foundation programs.
Dialysis treatment alone costs US$72,000 per person per year, according to the US Renal Data System. Diabetes accounts for 44 percent of chronic kidney disease cases in USA.
Dr Lipscombe said PromarkerD was a major weapon in the battle against the diabetes epidemic. “Regular testing and early diagnosis of diabetic kidney disease with PromarkerD can help millions of people avoid costly and invasive dialysis treatment or a kidney transplant,” he said.
For every million people living with diabetes, 10 per cent — or 100,000 people — are expected to suffer a rapid decline in kidney function within the next four years.
The PromarkerD test is able to predict this decline in kidney function in 86 per cent of cases.
This means that, for example, if every one of the 30 million Americans with diabetes took the test it would potentially identify 2.6 million of the 3 million people on the path to kidney disease. Those identified would require systematic re-testing to verify effectiveness of treatments. Another 84 million American adults — more than 1 out of 3 — have prediabetes, a precursor to diabetes, may also benefit from taking the PromarkerD test.
Dr Lipscombe said the breakthrough deal for PromarkerD in the USA and Mexico is important because it paves the way for other licensing contracts. “It is great to see PromarkerD launching in the world’s largest healthcare market as we further negotiations to commercialise the test in other countries including Japan, Australia, China and Europe.”
PromarkerD (www.PromarkerD.com)
PHDx, Inc (www.phdxinc.com)
Patia Biopharma (www.patiadiabetes.com)
Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)
For further information please contact:
Chuck Morrison
Head of Business Development
Proteomics International
E: c.morrison@proteomicsinternational.com
T: +1-617-331-2975
Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
E: team@dmgpr.com
T: (USA) 415-951-3228
T: (AU) 02-8218-2144
